Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LOXO-260 |
Synonyms | |
Therapy Description |
LOXO-260 is a selective RET inhibitor with activity against RET solvent front and gatekeeper mutations and fusions, with potential anti-tumor activity (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS8595). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LOXO-260 | LOXO260|LOXO 260|LOX-19260|LY3838915 | RET Inhibitor 53 | LOXO-260 is a selective RET inhibitor with activity against RET solvent front and gatekeeper mutations and fusions, with potential anti-tumor activity (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS8595). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05241834 | Phase I | LOXO-260 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | Active, not recruiting | USA | 0 |